Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot could simplify breast cancer treatment before surgery

NCT ID NCT07166185

Disease control Sponsor: Blida 1 University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a drug called Phesgo, given as a shot under the skin, for women with early-stage HER2-positive breast cancer before they have surgery. About 70 women in Algeria will receive Phesgo along with standard chemotherapy for about 18 weeks. The main goal is to see how many women have no cancer left in the breast or lymph nodes after treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Phesgo (a combination of trastuzumab and pertuzumab given as a shot under the skin)
What this could lead to
If this works, it could show that a simpler, faster shot can replace longer IV treatments for HER2-positive breast cancer before surgery, making care easier for patients and hospitals.
What could go wrong
This is a small, early-phase study with only 70 women in Algeria. It may not prove the treatment works better than standard care, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult female patients diagnosed with HER2-positive, non-metastatic breast cancer and eligible for neoadjuvant therapy according to local clinical practice in Algeria. Participants will be recruited from three oncology centers: Anti Cancer Center of Blida, public hospital of Aïn Defla, and public hospital of Médéa.

Ages

19 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female participants aged 19 years or older. * Histologically confirmed HER2-positive breast cancer (by immunohistochemistry and/or in situ hybridization), non-metastatic. * Candidate for neoadjuvant therapy according to local clinical practice. * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2. * Left ventricular ejection fraction (LVEF) ≥ 50%. * Signed written informed consent. Exclusion Criteria: * Evidence of distant metastases. * Prior anti-HER2 therapy. * Known contraindications to trastuzumab or pertuzumab. * Pregnancy or breastfeeding. * Disease progression during neoadjuvant treatment (if already started). * Refusal of surgery. * Withdrawal of consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non metastatic HER2 positive breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm HER2 positive breast carcinoma Pathologic Complete Response

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non metastatic HER2 positive breast cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Medical oncology department - Anti Cancer Center of Blida

    RECRUITING

    Blida, 09000, Algeria

More trials for these conditions

Other studies related to the condition(s) this trial covers.